Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Bell Tolls For Fedratinib In A Setback For Sanofi’s Oncology Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has halted clinical trials testing its Phase III JAK2 inhibitor fedratinib after determining that the risks of treatment outweigh the benefit after cases of the neurological condition Wernicke’s encephalopathy emerged in patients.

Advertisement

Related Content

Sanofi Oncology Strategy: A New Lease On Cancer R&D
On The Offense: Sanofi Suits Up For A Game Change
Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term
Sanofi Buys TargeGen And Its Lead Myelofibrosis Drug For $75 Million Upfront

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel